Literature DB >> 2429080

Acute doxorubicin cardiotoxicity: functional, metabolic, and morphologic alterations in the isolated, perfused rat heart.

P C Pelikan, M L Weisfeldt, W E Jacobus, M V Miceli, B H Bulkley, G Gerstenblith.   

Abstract

The acute effects of doxorubicin on coronary perfusion and left ventricular pressures and intracellular phosphate metabolite levels, the latter obtained by 31P nuclear magnetic resonance, were measured simultaneously in isolated, isovolumic rat hearts (Langendorf preparation) perfused at constant flow. Nineteen experimental hearts were perfused for 70 min with oxygenated HEPES-buffered solution containing 6 mg/L doxorubicin. These were compared with 18 control hearts (C), perfused under identical conditions but without doxorubicin, by repeated measures analysis of variance. In the experimental group, coronary perfusion pressure steadily increased to 226.3 +/- 13.8% (mean +/- SEM) of initial levels (p less than 0.0001 vs. C). Because flow was constant, the increase in coronary perfusion pressure in experimental hearts indicates a greater than twofold increase in coronary resistance. Intracellular phosphocreatine and ATP decreased to 80.3 +/- 3.9% (p less than 0.005 vs. C) and 82.1 +/- 6.4% (p less than 0.05 vs. C), whereas inorganic phosphate increased to 149.7 +/- 19.1% (p less than 0.05 vs. C) of initial levels, respectively. Accompanying these changes, diastolic pressure steadily increased to 521.7 +/- 91.4% of initial levels (p less than 0.0001 vs. C). Developed pressure initially increased to 107.1 +/- 4.5% at 30 min, and thereafter decreased to 76.2 +/- 6.3% at 70 min (p less than 0.05 vs. C). Typical structural alterations in myocyte nuclei were noted. Cellular calcium was not increased in doxorubicin-exposed hearts. Thus, acute doxorubicin cardiotoxicity is characterized by an increase in coronary resistance and is closely correlated with alterations in ventricular function and a decrease in intracellular high-energy phosphate content.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429080

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

1.  Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women.

Authors:  Y Cottin; C Touzery; B Coudert; S Richebourg; M Cohen; M Toubeau; P Louis; J E Wolf; F Brunotte
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin.

Authors:  W Kang; M Weiss
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

Review 3.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

Review 4.  Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.

Authors:  Ronny S Jiji; Christopher M Kramer; Michael Salerno
Journal:  J Nucl Cardiol       Date:  2012-04       Impact factor: 5.952

5.  Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function.

Authors:  P S Mushlin; B J Cusack; R J Boucek; T Andrejuk; X Li; R D Olson
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

6.  Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity.

Authors:  Jinping Gao; Ye Xiong; Ye-Shih Ho; Xuwan Liu; Chu Chang Chua; Xingshun Xu; Hong Wang; Ronald Hamdy; Balvin H L Chua
Journal:  Biochim Biophys Acta       Date:  2008-06-11

8.  Impairment of diastolic function during short-term anthracycline chemotherapy.

Authors:  Y Cottin; C Touzery; B Coudert; A Gilles; P Walker; J L Massing; M Toubeau; A Riedinger-Berriolo; D Caillot; P Louis
Journal:  Br Heart J       Date:  1995-01

9.  Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

10.  Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity.

Authors:  Ashish Gupta; Cory Rohlfsen; Michelle K Leppo; Vadappuram P Chacko; Yibin Wang; Charles Steenbergen; Robert G Weiss
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.